Vuja De Sciences
Biotechnology, 827 Bloomfield St, Hoboken, New Jersey, 07030, United States, 1-10 Employees
Who is VUJA DE SCIENCES
Vuja De is dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence. Our strategy is to develop products first for osteosarcoma, a rare bone can...
Read More
-
Headquarters: 827 Bloomfield St, Hoboken, New Jersey, 07030, United States
-
Date Founded: 2017
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
Does something look wrong? Fix it. | View contact records from VUJA DE SCIENCES
Vuja De Sciences Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Vuja De Sciences
Answer: Vuja De Sciences's headquarters are located at 827 Bloomfield St, Hoboken, New Jersey, 07030, United States
Answer: Vuja De Sciences's official website is https://vujade-life.com
Answer: Vuja De Sciences's revenue is Under $1 Million
Answer: Vuja De Sciences's SIC: 8731
Answer: Vuja De Sciences has 1-10 employees
Answer: Vuja De Sciences is in Biotechnology
Answer: Vuja De Sciences contact info: Phone number: Website: https://vujade-life.com
Answer: Vuja De is dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence. Our strategy is to develop products first for osteosarcoma, a rare bone cancer that largely effects adolescents, and then extend to other cancers. We utilize leading laboratory technologies for metastatic preclinical endpoints in combination with Comparative Oncology to de-risk and inform product development and maximize likelihood for successful human oncology clinical trials. We are testing repurposed drugs that have previously been in human clinical trials, as well as novel preclinical drugs. In Comparative Oncology, canine patients with naturally occurring cancer are included in clinical trials for benefit of humans and human's best friend. Dog osteosarcoma is highly relevant to human osteosarcoma; drugs effective in the dog are highly relevant to the human. A further advantage of dogs that is crucial in cancer recurrence trials is the that fact that in dogs the cancer process is sped up, so that what happens over a time frame of a few years in humans is compressed into months in dogs.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month